Another Interesting report from Suppversity:
Low dose of malaria drug chloroquine is associated with favourable effects on lipoprotein metabolism without significant influence on insulin resistance
A clinical trial of daily 250 mg of chloroquine diphosphate in patients with systemic lupus erythematosus showed significantly higher HDL cholesterol levels (27%) and lower levels of triglycerides (17%) in chloroquine-treated patients. Another study of high-dose chloroquine (250 mg four times daily for 3 days) in patients with diabetes showed a significant decrease in total cholesterol (8%) and LDL cholesterol (10%) levels. There was also a decrease in fasting plasma glucose levels (17%) and a corresponding increase in fasting plasma insulin levels (17%). These reductions were of a greater magnitude than those found in our study, due to the higher doses used.
A longitudinal study of 24 patients with systemic lupus erythematosus on hydroxychloroquine reported a significant decrease in cholesterol (7.6%) and LDL cholesterol levels (13.7%) after 3 months of daily therapy. There was also a significant decrease in the frequency of dyslipidaemia (26% vs. 12.5%) in hydroxychloroquine-treated participants. Epidemiological studies have also shown a reduction of diabetes risk with hydroxychloroquine.
The effect of chloroquine in lipid and glucose parameters might be time-dependent, as already described in patients with systemic lupus erythematosus after long-term therapy. Therefore, chloroquine given for more than 12 weeks might result in more significant effects.
More recent data indicates that healthy participants treated with low-dose chloroquine (300mg) weekly had small, but significantly decreased triglycerides and cholesterol ratio, with lower LDL levels than controls.
www.suppversity.com | Lee, L. S. U., et al. "Low‐dose chloroquine is associated with favourable effects on lipoprotein metabolism without significant influence on insulin resistance." Diabetic Medicine (2015).
https://www.facebook...46015615430587/